Quick answers
- What is Deferiprone used for?
- The FDA-approved label (Ferriprox, Chiesi USA, Inc., January 28, 2026) says: “FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Deferiprone have a boxed warning?
- Yes. The FDA label for Ferriprox has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Deferiprone?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Deferiprone been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Deferiprone?
- 5 companies list prescription products of Deferiprone in the FDA NDC Directory, including Chiesi USA, Inc., Sun Pharmaceutical Industries, Inc. and Dr. Reddy's Laboratories Inc..
What Deferiprone is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. …
— FDA label: Ferriprox, Chiesi USA, Inc., effective January 28, 2026. Read the full label on DailyMed →
The FDA has 7 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
7 of 7 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet · Tablet, coated · Tablet, film coated · Solution |
|---|---|
| Route | Oral |
| Prescription products | 10 in the FDA NDC Directory |
| Brand names | Ferriprox |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Chiesi USA, Inc.3 products
- Sun Pharmaceutical Industries, Inc.2 products
- Dr. Reddy's Laboratories Inc.2 products
- Hikma Pharmaceuticals USA Inc.2 products
- AvKARE1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021825 FERRIPROX | Chiesi | October 14, 2011 | 8, latest March 26, 2025 2025: Labeling · 2021: Labeling · 2021: Efficacy |
| NDA208030 FERRIPROX | Chiesi | September 9, 2015 | 5, latest March 26, 2025 2025: Labeling · 2021: Labeling · 2021: Efficacy |
| NDA212269 FERRIPROX | Chiesi | May 19, 2020 | 3, latest March 26, 2025 2025: Labeling · 2021: Labeling · 2021: Efficacy |
Generic approvals (3)
- ANDA208800Taro · February 8, 2019
- ANDA213239Hikma · March 29, 2021
- ANDA220132Pharmazone · December 11, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ferriprox, Chiesi USA, Inc., effective January 28, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →